glp 1 and satiety Potential mechanisms of weight loss caused by the effects of GLP‐1 GLP-1 and Anesthesia: Considerations and

The bidirectional relationship between depression and diabetes The relationship between diabetes and depression is profoundly bidirectional, with each condition influencing the onset and progression of the other [12, 29, 30]

This could include: Heart rate assessment at 4-8 weeks after initiation or dose escalation Periodic electrocardiography if arrhythmias are suspected Patient self-monitoring of pulse if symptomatic palpitations occur Evaluation of heart rate control in patients with atrial fibrillation When evaluating tachycardia in patients on GLP-1 therapy, clinicians should assess for other potential causes, including dehydration (especially from GI side effects), anemia, hyperthyroidism, stimulant use, infection, or other medications

Liraglutide (Saxenda) : Begins at 0.6 mg daily , increasing to a target dose of 3.0 mg per day

42,43 Dulaglutide (Trulicity , Eli Lilly and Company, Indianapolis, IN, USA) was as a treatment for type 2 diabetes in 2014

Clinical trials have reported decreases in high-sensitivity C-reactive protein (hs-CRP), a well-established biomarker of systemic inflammation and cardiovascular risk

Weight loss continues progressively for 12 to 18 months before plateauing, with maximal effects requiring sustained treatment at maintenance doses